Journal
INVESTIGATIVE RADIOLOGY
Volume 44, Issue 3, Pages 146-150Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLI.0b013e318195886d
Keywords
molecular MRI; fibrin-specific contrast agent; deep vein thrombosis; interventional radiology
Funding
- EPIX Pharmaceuticals. Lexington, MA
- German Research Council [SP634/2-1]
Ask authors/readers for more resources
Purpose: To evaluate the value of a fibrin-specific MR contrast agent (EP-2104R; EPIX Pharmaceuticals) for detection of deep vein thrombosis (DVT) and monitoring of percutaneous intervention for treatment. Materials and Methods: In 6 domestic swine, DVT was induced in an iliac/femoral vein using an occlusion-balloon catheter and subsequent injection of thrombin. The occluded vessels were recanalized by mechanical thrombectomy using a Fogarty catheter and an Arrow rotating thrombectomy device. Magnetic resonance imaging of the pelvis and lung was repeated 4 times (before and after DVT induction, after contrast agent administration, and after intervention) using a 1.5-T whole-body XMR system (ACS-NT, Philips Medical Systems, Best, NL). The visualization of the thrombi and contrast-to-noise ratio (CNR) was assessed. Results: EP-21048 allowed selective visualization of thrombi with accurate determination of the extent of DVT with high contrast (CNR: 65.3 +/- 17.2). After intervention, dislodged thrombus fragments were selectively visualized in the lung (CNR: 27.9 +/- 9.3). Conclusions: Molecular magnetic resonance imaging using fibrin-specific MR contrast agent EP-21048 allowed for selective visualization of DVT and monitoring of percutaneous intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available